On Thursday, Granules India has announced that its wholly owned subsidiary Granules Pharmaceuticals (GPI) has entered into an agreement with the US based USpharma for acquiring 12.5% of its stake.

The financial details of the transaction has not been by the company.

The company management has said that this investment will be enabling Granules to participate in product selection and have the right of first refusal to market the select products that are under development by USpharma.

Read EquityPandit’s Technical Analysis on Nifty Pharma